IPSC Stock Overview
A biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Century Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.97 |
| 52 Week High | US$5.51 |
| 52 Week Low | US$1.28 |
| Beta | 1.45 |
| 1 Month Change | -1.98% |
| 3 Month Change | -30.12% |
| 1 Year Change | -6.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.99% |
Recent News & Updates
Recent updates
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Shareholder Returns
| IPSC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -0.4% | -0.6% |
| 1Y | -6.0% | 5.4% | 22.5% |
Return vs Industry: IPSC underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: IPSC underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| IPSC volatility | |
|---|---|
| IPSC Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IPSC's share price has been volatile over the past 3 months.
Volatility Over Time: IPSC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 159 | Brent Pfeiffenberger | www.centurytx.com |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.
Century Therapeutics, Inc. Fundamentals Summary
| IPSC fundamental statistics | |
|---|---|
| Market cap | US$247.03m |
| Earnings (TTM) | -US$133.47m |
| Revenue (TTM) | US$1.37m |
180.3x
P/S Ratio-1.9x
P/E RatioIs IPSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPSC income statement (TTM) | |
|---|---|
| Revenue | US$1.37m |
| Cost of Revenue | US$91.23m |
| Gross Profit | -US$89.86m |
| Other Expenses | US$43.61m |
| Earnings | -US$133.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | -6,559.27% |
| Net Profit Margin | -9,742.41% |
| Debt/Equity Ratio | 0% |
How did IPSC perform over the long term?
See historical performance and comparison